Avalyn Pharma Inc., a clinical-stage biopharmaceutical company pioneering inhaled therapies for treating pulmonary fibrosis, is set to begin trading on the Nasdaq Global Select Market under the ticker symbol "AVLN" on April 30, 2026.
The company has priced its upsized initial public offering of 16.67 million shares of its common stock at $18.00 per share. The offering is scheduled to close on May 1, 2026, and gross proceeds to Avalyn are expected to be $300 million.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com